ArticleVaccines2024

Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.

Zafer Sezer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.